CN Patent

CN104603130A — 人类组蛋白甲基转移酶ezh2抑制剂的盐形式

Assigned to Eisai R&D Management Co Ltd · Expires 2015-05-06 · 11y expired

What this patent protects

本发明提供了N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-4’-(吗啉基甲基)-[1,1’-联苯基]-3-甲酰胺氢溴酸盐。本发明还提供了该化合物的特定晶型。

USPTO Abstract

本发明提供了N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-4’-(吗啉基甲基)-[1,1’-联苯基]-3-甲酰胺氢溴酸盐。本发明还提供了该化合物的特定晶型。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN104603130A
Jurisdiction: CN
Classification: —
Expires: 2015-05-06
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.